Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Oct 25, 2023 7:06pm
122 Views
Post# 35701162

RE:RE:RE:RE:RE:RE:RE:RE:RE:National Bank Comments

RE:RE:RE:RE:RE:RE:RE:RE:RE:National Bank Comments
SPCEO1 wrote: Maybe a better deal that does not crush loyal shareholders can be arranged. One has to think they are trying to dilute us to avoid the potential consequences of shareholder revolt. But if this deal fails, a better solution for the shareholders they are crushing could potentially be put together. 

I am not sure how committed Cantor is to defending that $1 target price. I doubt they are very committed.




I cannot dream of how this deal will go through.  The stock is for sure going under $1 again after a 4-1 reverse split.  Knowing you pitched another better solution that was ignored makes this even worse.  We have to take action against the leadership before they completely destroy this company.  Can we take next steps to gather support to call a special meeting?  Can we replace the leaderhsip team?  Can we block this transaction from happening?
<< Previous
Bullboard Posts
Next >>